747786
Last Update Posted: 2019-01-07
Recruiting has ended
All Genders accepted | 18 Years + |
40 Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
Non Interventional Post Marketing Programme in Neuroendocrine Tumours
The purpose of this study, is to assess the safety and local tolerability of the long-term use of Somatuline Autogel when administered by patients or their partners ("Home Injection Group") and the safety and local tolerability in patients receiving their injection from a healthcare professional (HCP) ("Reference Group").
Eligibility
Relevant conditions:
Neuroendocrine Tumors
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov